Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: LEVEMIR

« Back to Dashboard
Levemir is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from three suppliers. There are ten patents protecting this drug.

This drug has seventy-three patent family members in twenty-eight countries.

The generic ingredient in LEVEMIR is insulin detemir recombinant. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the insulin detemir recombinant profile page.

Summary for Tradename: LEVEMIR

Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: see list8
2013 Sales:$1,547,629,000

Pharmacology for Tradename: LEVEMIR

Ingredient-typeInsulin
Drug ClassInsulin Analog

Clinical Trials for: LEVEMIR

The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes Mellitus

Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes
Status: Completed Condition: Type 2 Diabetes

Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
Status: Completed Condition: Alzheimer's Disease; Mild Cognitive Impairment

Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
Status: Completed Condition: Diabetes; Diabetes Mellitus, Type 2

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-001Jun 16, 2005RXYes5,750,497<disabled>YY<disabled>
Novo Nordisk Inc
LEVEMIR INNOLET
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-003Jun 16, 2005DISCNNo5,866,538<disabled>YY<disabled>
Novo Nordisk Inc
LEVEMIR FLEXPEN
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-002Jun 16, 2005RXYes5,866,538<disabled>YY<disabled>
Novo Nordisk Inc
LEVEMIR
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-001Jun 16, 2005RXYes<disabled><disabled>
Novo Nordisk Inc
LEVEMIR FLEXTOUCH
insulin detemir recombinant
INJECTABLE;SUBCUTANEOUS021536-005Oct 31, 2013RXYes8,684,969<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LEVEMIR

Country Document Number Publication Date
Denmark0792290Oct 01, 2001
Japan2009235075Oct 15, 2009
Japan2002308899Oct 23, 2002
Poland330763May 24, 1999
Bulgaria61611Jan 30, 1998
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc